Effects of anatabine and unilateral maximal eccentric isokinetic muscle actions on serum markers of muscle damage and inflammation

Nathaniel D M Jenkins; Terry J Housh; Kristen C Cochrane; Haley C Bergstrom; Daniel A Traylor; Robert W Lewis Jr; Samuel L Buckner; Richard J Schmidt; Glen O Johnson; Joel T Cramer

doi:10.1016/j.ejphar.2014.01.054

Back

Effects of anatabine and unilateral maximal eccentric isokinetic muscle actions on serum markers of muscle damage and inflammation

Journal article

Peer reviewed

Effects of anatabine and unilateral maximal eccentric isokinetic muscle actions on serum markers of muscle damage and inflammation

Nathaniel D M Jenkins, Terry J Housh, Kristen C Cochrane, Haley C Bergstrom, Daniel A Traylor, Robert W Lewis Jr, Samuel L Buckner, Richard J Schmidt, Glen O Johnson and Joel T Cramer

European journal of pharmacology, Vol.728(1), pp.161-166

04/05/2014

DOI: 10.1016/j.ejphar.2014.01.054

PMID: 24509134

View Online

Abstract

The purpose of this study was to examine the effects of anatabine supplementation in conjunction with unilateral, maximal eccentric isokinetic muscle actions on serum markers of muscle damage and pro-inflammatory cytokines in humans. Seventeen men (mean ± S.D. age = 22.4 ± 3.2 yrs) participated in this double-blinded, placebo-controlled, crossover study. Participants were randomly assigned to two 10-day conditions (anatabine and placebo) separated by a 2-4 week washout period. After seven days of supplementation, blood was sampled immediately prior to PRE, immediately following POST, and 24, 48, and 72 h after 6 sets of 10 repetitions of unilateral, maximal eccentric isokinetic forearm flexion exercise. Concentrations of serum creatine kinase, lactate dehydrogenase, myoglobin, high sensitivity c-reactive protein, and TNF-α were measured. Creatine kinase, myoglobin, and lactate dehydrogenase increased (P<0.05), while high sensitivity c-reactive protein and TNF-α did not change (P>0.05) after the eccentric exercise during both conditions. Lactate dehydrogenase was higher (P<0.05) during the anatabine condition. The primary findings of this study were two-fold: (a) anatabine had no beneficial effects on traditional markers of muscle damage (creatine kinase, lactate dehydrogenase, and myoglobin) compared to placebo after the eccentric exercise protocol, and (b) the eccentric exercise protocol did not elicit increase in the pro-inflammatory cytokines (c-reactive protein and TNF-α). Future studies are needed to examine the effects of anatabine on naturally-occurring inflammation that is common with aging or obesity. Furthermore, additional research is needed to examine the relationship between muscle damage and inflammation after eccentric exercises of different modes, durations, and intensities.

Adult

Alkaloids - administration & dosage

Alkaloids - pharmacology

Anti-Inflammatory Agents, Non-Steroidal - administration & dosage

Anti-Inflammatory Agents, Non-Steroidal - pharmacology

Biomarkers - blood

Cross-Over Studies

Cytokines - blood

Dietary Supplements

Double-Blind Method

Exercise - physiology

Humans

Male

Muscle Contraction - drug effects

Muscle Contraction - immunology

Muscle, Skeletal - drug effects

Muscle, Skeletal - enzymology

Muscle, Skeletal - immunology

Muscle, Skeletal - injuries

Pyridines - administration & dosage

Pyridines - pharmacology

Time Factors

Treatment Outcome

Young Adult

Details

Title: Subtitle: Effects of anatabine and unilateral maximal eccentric isokinetic muscle actions on serum markers of muscle damage and inflammation
Creators: Nathaniel D M Jenkins - University of Nebraska–Lincoln
Terry J Housh - University of Nebraska–Lincoln
Kristen C Cochrane - University of Nebraska–Lincoln
Haley C Bergstrom - University of Nebraska–Lincoln
Daniel A Traylor - University of Nebraska–Lincoln
Robert W Lewis Jr - University of Nebraska–Lincoln
Samuel L Buckner - University of Nebraska–Lincoln
Richard J Schmidt - University of Nebraska–Lincoln
Glen O Johnson - University of Nebraska–Lincoln
Joel T Cramer - University of Nebraska–Lincoln
Resource Type: Journal article
Publication Details: European journal of pharmacology, Vol.728(1), pp.161-166
DOI: 10.1016/j.ejphar.2014.01.054
PMID: 24509134
NLM abbreviation: Eur J Pharmacol
ISSN: 0014-2999
eISSN: 1879-0712
Language: English
Date published: 04/05/2014
Academic Unit: Center for Social Science Innovation; Injury Prevention Research Center; Health, Sport, and Human Physiology
Record Identifier: 9984259393002771

Metrics

18 Record Views

3 Times Cited - Web of Science